Status:
COMPLETED
Effects of Intermittent Fasting on Fatty Liver Disease
Lead Sponsor:
Beijing Chao Yang Hospital
Conditions:
Sensitivity to Thyroid Hormones
Metabolic Parameters
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Eighty subjects with FLD were recruited from the endocrinology clinic at Beijing Chao-yang Hospital. All of the following inclusion criteria needed to be met: hepatic fat content (HFC) were upper 5.0%...
Detailed Description
Eighty subjects with FLD were recruited from the endocrinology clinic at Beijing Chao-yang Hospital, Capital Medical University, China, between September 22, 2020 and April 30, 2021. Inclusion criteri...
Eligibility Criteria
Inclusion
- hepatic fat content (HFC) \> 5.0% evaluated by upper abdominal MRI proton density fat fraction (MRI-PDFF) examinations
- age ≥ 18 years
- body mass index (BMI) ≥ 18.5 kg/m2
- stable body weight (change \< ± 10% of body weight) during the last 3 months
Exclusion
- plasma aspartate aminotransferase (AST) and alanine amino-transferase (ALT) levels exceeded 2.5 times of the upper limit of normal
- fasting blood glucose (FBG) levels ≥ 7.0 mmol/L or glycated hemoglobin A1c (HbA1c) ≥ 6.5%
- with type 1 or type 2 diabetes
- with heart disease
- with other hepatic disease (excluding FLD)
- with renal disease
Key Trial Info
Start Date :
September 22 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2021
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04795973
Start Date
September 22 2020
End Date
April 30 2021
Last Update
September 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Chao-yang Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100020